AbbVie to Invest $380 Million in Chicago to Further Expand US API Manufacturing
Investment marks continued progress against AbbVie's $100 billion commitment to US R&D and capital investments, including manufacturing, over the next decade.
AbbVie recently announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.
Construction will begin in spring 2026, with both new facilities expected to be fully operational in 2029.
"This milestone demonstrates further progress against our $100 billion commitment to US R&D and capital investments over the next decade," said Robert A. Michael, Chairman and Chief Executive Officer, AbbVie. "By strengthening our US manufacturing capabilities, we are well-positioned to support our investment in innovation and enhance our ability to deliver next-generation medicines to patients."
Active pharmaceutical ingredient manufacturing is a complex, multi-step process that involves producing the active components responsible for a medication's therapeutic effects. Over the past six months, AbbVie has announced plans to significantly expand its API manufacturing capabilities and capacity in the US. In September 2025, AbbVie broke ground on the first phase of this investment, a new chemical synthesis facility that will enable the return of API production for select neuroscience, immunology, and oncology products from Europe and Asia to the US.
With a presence in all 50 states and Puerto Rico, AbbVie employs approximately 29,000 people in the US, including more than 6,000 at its US manufacturing sites. This investment helps to advance AbbVie's long-term commitment to Illinois, where it is headquartered and employs more than 11,500 people.
In addition to its planned investments in Illinois, AbbVie recently announced plans to acquire a device manufacturing facility in Arizona and to make significant investments at its manufacturing facility in Massachusetts. AbbVie is currently in discussions with multiple US states about potential manufacturing investments and anticipates announcing additional investments in 2026.
